Theriva Biologics Q3 2022 cash $50.5M; FDA clears Phase 2 trial for VCN-01 in PDAC

Theriva Biologics, Inc.

2022-Q3 EPS reported -$0.95

Cash and cash equivalents $50.5M as of Sep 30, 2022; expected runway into Q1 2024.
FDA and AEMPS cleared the planned Phase 2 trial of VCN-01 in pancreatic ductal adenocarcinoma patients.
SYN-004 Phase 1b/2a in allo-HCT: positive DSMC review for Cohort 1; first patient dosed in Cohort 2 (Oct 2022).
Company rebranded as Theriva Biologics and began trading under ticker TOVX on NYSE American in October 2022.
Anticipated near-term milestones: initiate VIRAGE Phase 2 for VCN-01 in PDAC Q4 2022; pre-IND meeting for retinoblastoma early 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Theriva Biologics, Inc. reported financial results for for the quarter ended September 30, 2022.

Period: for the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended September 30, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Theriva Biologics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-117256

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.